Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Study Type: Interventional"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Remission+Induction%22&type=Subject&filter%5B%5D=topic_facet%3A%22Study+Type%3A+Interventional%22
/vufind/Search/Results?lookfor=%22Remission+Induction%22&type=Subject&filter%5B%5D=topic_facet%3A%22Study+Type%3A+Interventional%22
Search /vufind/Search2/Results?lookfor=%22Remission+Induction%22&type=Subject&filter%5B%5D=topic_facet%3A%22Study+Type%3A+Interventional%22
PubPharm (48)
1
Phase II/III Study for Remission Induction With Bortezomib (Vel), Cyclophosphamide (C) and Dexamethasone (D) in Patients <= 60 Years With Untreated Multiple Myeloma and Planned High Dose Chemotherapy: (VelCD) : Phase II/III Study for Remission Induction With Bortezomib (Vel), Cyclophosphamide (C) and Dexamethasone (D) in Patients <= 60 Years With Untreated Multiple Myeloma and Planned High Dose Chemotherapy: (VelCD)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
2
Phase II/III Study for Remission Induction With Bortezomib (Vel), Cyclophosphamide (C) and Dexamethasone (D) in Patients <= 60 Years With Untreated Multiple Myeloma and Planned High Dose Chemotherapy: (VelCD) : Phase II/III Study for Remission Induction With Bortezomib (Vel), Cyclophosphamide (C) and Dexamethasone (D) in Patients <= 60 Years With Untreated Multiple Myeloma and Planned High Dose Chemotherapy: (VelCD)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
3
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial) : A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial) - Bortezomib for relapsed ALL (BZM-ALL-2)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
4
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial) : A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial) - Bortezomib for relapsed ALL (BZM-ALL-2)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
5
Study for assessing the effect of blood level guided adjustment of posconazole doses (an oral drug to prevent fungal infections) in preventing fungal infections in blood cancer patients : Single arm, single centre prospective study to assess the effect of therapeutic drug monitoring (TDM) based dosage adjustment of posaconazole on the incidence of invasive fungal infections (IFIs) in AML patients on induction chemotherapy on posaconazole prophylaxis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
6
Study for assessing the effect of blood level guided adjustment of posconazole doses (an oral drug to prevent fungal infections) in preventing fungal infections in blood cancer patients : Single arm, single centre prospective study to assess the effect of therapeutic drug monitoring (TDM) based dosage adjustment of posaconazole on the incidence of invasive fungal infections (IFIs) in AML patients on induction chemotherapy on posaconazole prophylaxis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
7
A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
8
A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
9
A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
10
A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
1
2
3
4
5
Nächster »
[5]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Study Type: Interventional
Medienart
48
Aufsätze
48
E-Artikel
48
E-Ressourcen
Zeitschriftentitel
48
WHO International Clinical Trials Registry Plat...
Thema
48
610
Study Type: Interventional
42
Recruitment Status: Not yet recruiting
30
Phase: Phase 3
10
Medical Condition: previously untreated acute m...
6
Phase: Phase 2
4
Medical Condition: Invasive fungal infections (...
4
Medical Condition: Invasive fungal infections (...
4
Medical Condition: previously untreated acute m...
4
Medical Condition: previously untreated acute m...
4
Recruitment Status: Complete: follow-up complete
2
Medical Condition: A high-risk group of pediatr...
2
Medical Condition: Health Condition 1: null- Ac...
2
Medical Condition: Invasive fungal infections (...
2
Medical Condition: Invasive fungal infections (...
2
Medical Condition: Invasive fungal infections (...
2
Medical Condition: Multiple Myeloma # Remission...
2
Medical Condition: Patients older than 60 years...
2
Medical Condition: previously untreated acute m...
2
Medical Condition: previously untreated acute m...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
28
2020-
20
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
46
Englisch
2
Spanisch
Haven't found what you're looking for?
Wird geladen...